Multiple sclerosis and celiac disease: Is there an increased risk?

Multiple Sclerosis

Volumn 10, Issue 6, 2004, Pages 711-712

  Salvatore, Silvia ^a   Finazzi, S ^b   Ghezzi, A ^c   Tosi, A ^a   Barassi, A ^a   Luini, C ^a   Bettini, B ^c   Zibetti, A ^c   Nespoli, L ^a   Melzi d'Eril, G V ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Ospedale di Legnano   (Italy)

^c Centro Studi   (Italy)

Author keywords

Celiac disease; Gastrointestinal disease; Interferon; Multiple sclerosis; Transglutaminase

Indexed keywords

ENZYME ANTIBODY; IMMUNOGLOBULIN A; INTERLEUKIN 1BETA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PREVALENCE; RISK ASSESSMENT;

ADULT; AUTOANTIBODIES; CELIAC DISEASE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREVALENCE; RISK FACTORS; TRANSGLUTAMINASES;

EID: 9744228672     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1113sr     Document Type: Article

References (17)

1. Ventura A, Magazzù G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. Gastroenterology 1999; 117: 297-303.
2. Hadjivassiliou M, Gibson A, Davies-Jones GAB, Lobo A, Stephenson TJ, Milford-Ward A. Does cryptic gluten sensitivity play a part in neurological illness. Lancet 1996; 347: 369-71.
3. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399: A40-A47.
4. Volta U, Bellentani S, Bianchi FB, Brandi G, De Franceschi L, Miglioli L et al. High prevalence of celiac disease in Italian general population. Dig Dis Sci 2001; 46: 1500-505.
5. Volta U, De Giorgio R, Petrolini N, Snghellini V, Barbara G, Granito A et al. Clinical findings and anti-neuronal antibodies in coeliac disease with neurological disorders. Scand J Gastroenterol 2002; 37: 1276-81.
6. Speciale L, Saresella M, Caputo D, Ruzzante S, Mancuso R, Calvo MG et al. Serum auto antibodies presence in multiple sclerosis patients treated with β-interferon 1a and 1b. Journal of NeuroVirology 2000; 6: 57-61.
7. Karow AC, Braun J, Marx P, Stangel M. Remission of a CNS inflammatory disease accompained by newly developed ANA and arthropaty during treatment with IFN-β. J Neurol 2002; 249: 1121-22.
8. Matheson NA. Multiple sclerosis and diet. Lancet 1974; 2: 831.
9. Lange LS, Shiner M. Small-bowel abnormalities in multiple sclerosis. Lancet 1976; 2: 1319-22.
10. Jones PE, Pallis C, Peters TJ. Morphological and biochemical findings in jejunal biopsies from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1979; 42: 402-406.
11. Salur L, Uibo O, Talvik I, Justus I, Metskula K, Talvik T, Uibo R. The high frequency of coeliac disease among children with neurological disorders. Eur J Neurology 2000; 7: 707-11.
12. Cross A, Golumbek P. Neurologic manifestations of celiac disease: proven or just a gut feeling? Neurology 2003; 60: 1566-68.
13. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D. Identification of tissue translutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.
14. Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol 1999; 94: 691-96.
15. Hin H, Bird G, Fisher P, Mahy N, Jewell D. Coeliac disease in primary care: case finding study. Br Med J 1999; 318: 164-67.
16. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002; 2: 647-55.
17. Barcellos LF, Oksemberg JR, Begovich AB. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Human Genet 2003; 72: 710-16.